 Home > Active Ingredient News > Blood System > AJH: Anti-myeloma treatment outcomes after BCMA CAR-T for multiple myeloma still need to be improved

AJH: Anti-myeloma treatment outcomes after BCMA CAR-T for multiple myeloma still need to be improved

 Last Update: 2022-10-12
 Source: Internet
 Author: User

Tags

a549 cell line

anti ssa antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Despite tremendous advances in the treatment of multiple myeloma (MM) over the past two decades and substantial improvements in outcomes, MM remains incurable, with disease progression

BCMA CAR-T cell therapy has shown encouraging results in relapsed/refractory MM, with a higher response rate of 73% to 95%

The American Journal of Hematology recently published an article by Professor Cuckoo of Shanghai Changzheng Hospital as the corresponding author, describing the outcomes of 20 patients receiving subsequent anti-myeloma therapies (sAMT) after the treatment of HDS269B in phase I/II clinical trials, and explored possible follow-up treatment strategies, but overall, CAR-T The best strategy for patients after treatment remains to be determined

References

Dongjian Chen, Xiaoxian,g Wang, Zhi Chen,et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.